Citigroup’s Amicus Therapeutics FOLD Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $1.45M | Hold |
100,000
| – | – | ﹤0.01% | 2874 |
|
|
2025
Q4 | $1.42M | Buy |
+100,000
| New | +$982K | ﹤0.01% | 2893 |
|
|
2025
Q1 | – | Sell |
-124,900
| Closed | -$1.18M | – | 5706 |
|
|
2024
Q4 | $1.18M | Buy |
124,900
+100
| +0.1% | +$1.04K | ﹤0.01% | 3234 |
|
|
2024
Q3 | $1.33M | Buy |
124,800
+94,900
| +317% | +$1.03M | ﹤0.01% | 3020 |
|
|
2024
Q2 | $297K | Sell |
29,900
-39,800
| -57% | -$409K | ﹤0.01% | 3688 |
|
|
2024
Q1 | $821K | Buy |
69,700
+10,900
| +19% | +$139K | ﹤0.01% | 3184 |
|
|
2023
Q4 | $834K | Sell |
58,800
-32,700
| -36% | -$371K | ﹤0.01% | 2982 |
|
|
2023
Q3 | $1.11M | Sell |
91,500
-21,200
| -19% | -$273K | ﹤0.01% | 2416 |
|
|
2023
Q2 | $1.42M | Buy |
112,700
+40,000
| +55% | +$475K | ﹤0.01% | 2538 |
|
|
2023
Q1 | $806K | Buy |
72,700
+12,700
| +21% | +$157K | ﹤0.01% | 2729 |
|
|
2022
Q4 | $733K | Buy |
60,000
+20,000
| +50% | +$225K | ﹤0.01% | 2898 |
|
|
2022
Q3 | $418K | Hold |
40,000
| – | – | ﹤0.01% | 3368 |
|
|
2022
Q2 | $430K | Buy |
+40,000
| New | +$329K | ﹤0.01% | 3346 |
|
|
2021
Q1 | – | Sell |
-15,200
| Closed | -$351K | – | 6640 |
|
|
2020
Q4 | $351K | Buy |
15,200
+8,600
| +130% | +$176K | ﹤0.01% | 4522 |
|
|
2020
Q3 | $93K | Sell |
6,600
-24,800
| -79% | -$361K | ﹤0.01% | 5172 |
|
|
2020
Q2 | $474K | Buy |
31,400
+4,100
| +15% | +$50K | ﹤0.01% | 4312 |
|
|
2020
Q1 | $252K | Sell |
27,300
-6,100
| -18% | -$58K | ﹤0.01% | 4535 |
|
|
2019
Q4 | $325K | Buy |
33,400
+8,500
| +34% | +$77.8K | ﹤0.01% | 4786 |
|
|
2019
Q3 | $200K | Buy |
24,900
+600
| +2% | +$6.51K | ﹤0.01% | 5145 |
|
|
2019
Q2 | $303K | Buy |
24,300
+7,100
| +41% | +$90.1K | ﹤0.01% | 4915 |
|
|
2019
Q1 | $234K | Sell |
17,200
-2,100
| -11% | -$25.7K | ﹤0.01% | 4944 |
|
|
2018
Q4 | $185K | Buy |
19,300
+8,900
| +86% | +$97.8K | ﹤0.01% | 5094 |
|
|
2018
Q3 | $126K | Sell |
10,400
-32,300
| -76% | -$452K | ﹤0.01% | 5679 |
|
|
2018
Q2 | $667K | Sell |
42,700
-21,600
| -34% | -$327K | ﹤0.01% | 3788 |
|
|
2018
Q1 | $967K | Sell |
64,300
-9,000
| -12% | -$137K | ﹤0.01% | 3276 |
|
|
2017
Q4 | $1.05M | Buy |
73,300
+32,400
| +79% | +$445K | ﹤0.01% | 3287 |
|
|
2017
Q3 | $617K | Sell |
40,900
-51,200
| -56% | -$677K | ﹤0.01% | 3889 |
|
|
2017
Q2 | $927K | Sell |
92,100
-86,700
| -48% | -$698K | ﹤0.01% | 3399 |
|
|
2017
Q1 | $1.27M | Buy |
178,800
+97,300
| +119% | +$615K | ﹤0.01% | 2969 |
|
|
2016
Q4 | $405K | Buy |
81,500
+70,400
| +634% | +$487K | ﹤0.01% | 4605 |
|
|
2016
Q3 | $82K | Sell |
11,100
-9,300
| -46% | -$62.8K | ﹤0.01% | 5329 |
|
|
2016
Q2 | $111K | Sell |
20,400
-10,700
| -34% | -$74.8K | ﹤0.01% | 4987 |
|
|
2016
Q1 | $263K | Buy |
31,100
+7,100
| +30% | +$50.3K | ﹤0.01% | 4826 |
|
|
2015
Q4 | $233K | Buy |
24,000
+18,400
| +329% | +$166K | ﹤0.01% | 4593 |
|
|
2015
Q3 | $78K | Sell |
5,600
-2,200
| -28% | -$34.5K | ﹤0.01% | 5128 |
|
|
2015
Q2 | $110K | Buy |
+7,800
| New | +$93.8K | ﹤0.01% | 4918 |
|
Other funds holding FOLD
VCM
PCM
VPM
GCL
Citigroup's FOLD Position: Q1 2026 in Review
Citigroup increased its Amicus Therapeutics (FOLD) stake by 156% in Q1 2026, buying an estimated $37M and bringing the position to 4,226,882 shares worth $61.1M. The position accounts for 0.03% of the portfolio, ranked #566.
Citigroup first reported a position in FOLD in Q2 2013 and has held it in 51 quarters since. 298 funds tracked by Wall St. Rank hold FOLD as of Q1 2026.
- Citigroup held 4,226,882 shares of Amicus Therapeutics worth $61.1M as of Q1 2026.
- Citigroup bought 2,578,335 Amicus Therapeutics shares in Q1 2026, an estimated $37M.
- Amicus Therapeutics made up 0.03% of Citigroup's portfolio in Q1 2026, its #566 holding.
- Citigroup first reported a position in Amicus Therapeutics in Q2 2013 and has held it in 51 quarters since.
- 298 funds tracked by Wall St. Rank held Amicus Therapeutics as of Q1 2026.
Based on Citigroup's 13F filing for Q1 2026, filed 11 May 2026.